InsidersTradesSigma
Follow the Rapid Micro Biosystems, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Rapid Micro Biosystems, INC. has published 103 reports. Market capitalisation: €99.1m. The latest transaction was disclosed on 24 July 2026 (Levée d'options). Among the most active insiders: Spignesi Robert G. Jr.. All data is free.
103
Insider Decl.
n/a
Thresholds
€478,208
16 ops.
Buy Volume
€564,766
10 ops.
Sell Volume
41Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,948 of 29,024 companies
3.7
score / 100
Value5
Quality3
FCF yld-41%
Earn yld-60%
EV/EBITDA·
ROE-142%
Gross mgn3.1%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 July 2026
Declarations103 total
1,681 shares@ US$0.750.0012% mcap2.1% of flowClass A Common StockSEC:0001415666-26-000008:0
1,827 shares@ US$0.750.0013% mcap2.3% of flowClass A Common StockSEC:0001415666-26-000008:1
1,402 shares@ US$0.750.0010% mcap0.2% of flowClass A Common StockSEC:0001853904-26-000020:0
10,000 shares@ US$1.70440.020% mcap16.4% of flowClass ASEC144:0001959173-26-005162
6,312 shares@ US$1.750.011% mcap5.7% of flowClass ASEC144:0001959173-26-005011
3,688 shares@ US$1.750.0063% mcap3.2% of flowClass ASEC144:0001959173-26-004811
5,000 shares@ US$1.86980.0092% mcap4.4% of flowClass ASEC144:0001959173-26-004536
19,300 shares0Class A Common StockSEC:0002070373-26-000003:0
9,603 shares@ US$4.318122.4% of flowClass A Common StockSEC:0001872301-26-000012:0
17,922 shares@ US$4.111512.6% of flowClass A Common StockSEC:0001853904-26-000013:0
7,480 shares@ US$4.318114.5% of flowClass A Common StockSEC:0001289733-26-000011:0
842 shares@ US$0.75100.0% of flowClass A Common StockSEC:0001107158-26-000002:0
5,403 shares@ US$3.92311.3% of flowClass A Common StockSEC:0001872301-26-000009:0
38,327 shares@ US$3.885325.0% of flowClass A Common StockSEC:0001853904-26-000010:0
17,254 shares@ US$3.92329.9% of flowClass A Common StockSEC:0001289733-26-000008:0
74,000 shares0Class A Common StockSEC:0001380106-26-000017:0
97,000 shares0Class A Common StockSEC:0001380106-26-000015:0
264,000 shares0Class A Common StockSEC:0001380106-26-000013:0
4,610 shares@ US$3.78279.2% of flowClass A Common StockSEC:0001872301-26-000005:0
12,840 shares@ US$3.78278.1% of flowClass A Common StockSEC:0001853904-26-000004:0
6,027 shares@ US$3.782710.0% of flowClass A Common StockSEC:0001289733-26-000004:0
49,000 shares@ US$3.879485.7% of flowClass A Common StockSEC:0001193125-26-041248:0
629,032 shares@ US$0.0514.3% of flowClass A Common StockSEC:0001193125-26-036387:0
40,000 shares0Class A Common StockSEC:0001380106-25-000203:0
3,400 shares@ US$0.750.8% of flowClass A Common StockSEC:0001380106-25-000190:0
25 of 103 declarations
About Rapid Micro Biosystems, INC.
Rapid Micro Biosystems, Inc. is a U.S.-based life sciences technology company listed on the Nasdaq under the ticker RPID in the United States. The company operates in a specialized segment of healthcare manufacturing automation: microbial quality control (“MQC”) testing for pharmaceutical and biopharmaceutical production. Its core end markets include biologics, vaccines, cell and gene therapies, and sterile injectables, where speed, data integrity, and regulatory compliance are critical. Founded in 2006 and incorporated in Delaware, Rapid Micro Biosystems built its business around the Growth Direct® platform, a proprietary system designed to automate historically manual and error-prone microbiology workflows. The platform modernizes routine QC testing such as environmental monitoring, water testing, and bioburden testing. By bringing QC automation closer to the manufacturing floor, the system is intended to reduce release-cycle time, improve accuracy, enhance data integrity, and lower the operational risk associated with contamination events and production downtime. For investors, the appeal is that this is a mission-critical application rather than a discretionary tool: once embedded in a manufacturing network, the platform can become part of a customer’s long-term quality infrastructure. The company is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell, Massachusetts, and international locations in Switzerland, Germany, and the Netherlands. That footprint reflects a commercial model aimed at global pharmaceutical and biotech customers with multi-site manufacturing operations. Rapid Micro Biosystems has also emphasized recurring revenue from consumables and service contracts, which is important because it can create a more durable revenue stream than one-off system placements alone. In competitive terms, Rapid Micro Biosystems occupies a narrow but differentiated niche at the intersection of automation, microbiology, and regulated manufacturing. Its value proposition is centered on replacing slow manual testing with a growth-based automated platform that can improve efficiency, throughput, compliance, and decision-making. Recent company disclosures indicate continued traction with large global customers. In March 2026, management reported record fourth-quarter and full-year 2025 results and issued 2026 guidance calling for higher revenue and more Growth Direct placements. The company also highlighted significant multi-system orders from Amgen and Samsung Biologics, which is notable because it suggests expanding enterprise-level adoption rather than isolated pilot use. Overall, Rapid Micro Biosystems remains a specialized growth story on Nasdaq in the United States, with meaningful exposure to biopharma capital spending, recurring consumables, and the gradual automation of quality control workflows across large manufacturing networks.
